SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 769.
  • 2
    James PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004; 11: 38.
  • 3
    Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006; 295: 154955.
  • 4
    Hubert H, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 96877.
  • 5
    Lean ME, Han TS, Seidell JC. Impairment of health and quality of life in people with large waist circumference. Lancet 1998; 351: 8536.
  • 6
    Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 7907.
  • 7
    Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res 2003; 11: 122331.
  • 8
    World Health Organization. Obesity: Preventing and managing the global epidemic. (Report of a WHO Consultation on Obesity, Geneva, 3–5 June 1997). Geneva: WHO, 1998.
  • 9
    Baumgartner RN, Heymsfield SB, Roche AF. Human body composition and the epidemiology of chronic disease. Obes Res 1995; 3: 7395.
  • 10
    Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142: 52531.
  • 11
    Bravata DM, Sanders L, Huang J, Krumholz HM, Olkin I, Gardner CD, Bravata DM. Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA 2003; 289: 183750.
  • 12
    Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams T, Williams M, Gracely EJ, Stern L. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003; 348: 207481.
  • 13
    Yancy WS Jr, Olsen MK, Guyton JR, Bakst RP, Westman EC. A low carbohydrate,ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 2004; 140: 76977.
  • 14
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 211120.
  • 15
    Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397415.
  • 16
    Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997; 21: s59.
  • 17
    Leung WYS, Thomas GN, Chan JCN, Tomlinson B. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clinical Therapeutics 2003; 25: 5880.
  • 18
    Bray GA. Drug insight: appetite suppressants. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 8995.
  • 19
    Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006; 29: 277302.
  • 20
    Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119: 70713.
  • 21
    Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 26273.
  • 22
    Valle-Jones JC, Brodie NH, O'Hara H, O'Hara J, McGhie RL. A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice. Pharmatherapeutica 1983; 3: 3004.
  • 23
    Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 5818.
  • 24
    Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Meta-analysis pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 53246.
  • 25
    Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 2000; 1: 12739.
  • 26
    Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 9941003.
  • 27
    McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998; 56: 1093124.
  • 28
    Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes Relat Metab Disord 2005; 29: 50916.
  • 29
    Nakou E, Filippatos TD, Liberopoulos EN, Tselepis AD, Kiortsis DN, Mikhailidis DP, Elisaf MS. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother 2008; 9: 162939.
  • 30
    Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Krüger N, Strauss A, Stoffels G, Luft FC, Jordan J. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 2006; 79: 5008.
  • 31
    Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P; SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007; 28: 291523.
  • 32
    Pagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonizing cannabinoid type 1 receptors. Lancet 2005; 365: 13634.
  • 33
    European Medicines Agency. The European Medicines Agency recommends suspension of the marketing authorization of Acomplia. [press release] Oct 23, 2008. Available at: http://www.emea.europa.eu (Doc. Ref.: EMEA/CHMP/537777/2008).
  • 34
    Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 77184.
  • 35
    Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rösser S, for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 138997.
  • 36
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, for RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 76175.
  • 37
    Despres JP, Golay A, Sjostrom L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 212134.
  • 38
    Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 166072.
  • 39
    Samat A, Tomlinson B, Taheri S, Thomas GN. Rimonabant for the treatment of obesity. Recent Pat Cardiovas Drug Discov 2008; 3: 18793.
  • 40
    Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21: s1223.
  • 41
    Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 825.
  • 42
    US Food and Drug Administration. FDA approves orlistat for obesity. [press announcement] Febuary 7, 2007. Available at http://www.fda.gov/bbs/topics/NEWS/2007/NEW01557.html.
  • 43
    Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 15561.
  • 44
    Schneider R, Golzman B, Turkot S, Kogan J, Oren S. Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci 2005; 330: 15760.
  • 45
    Beck-da-Silva L, Higginson L, Frasser M, Williams K, Haddad H. Effect of orlistat in obese patients with heart failure: a pilot study. Congest Heart Fail 2005; 11: 11823.
  • 46
    Shi YF, Pan CY, Hill J, Gao Y. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed type 2 diabetes. Diabetic Med 2005; 22: 173743.
  • 47
    Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293: 287383.
  • 48
    Maahs D, De Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, Schade DS. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006; 12: 1828.
  • 49
    Hirsch B. Review of anti-obesity medications currently under development. Am J Bar Med 2000; 15: 1623.
  • 50
    Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 2006; 5: 91931.
  • 51
    Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LH, Goulet MT, Hagmann WK, Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Francis B, Strack AM, MacIntyre DE, Shearman LP. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 2007; 321: 101322.
  • 52
    Melnikova I, Wages D. Anti-obesity therapies. Nat Rev Drug Discov 2006; 5: 36970.
  • 53
    Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. Int J Clin Pract Suppl 2007; 154: 1928.
  • 54
    Palamara KL, Mogul HR, Peterson SJ, Frishman WH. Obesity: new perspectives and pharmacotherapies. Cardiol Rev 2006; 14: 23858.
  • 55
    Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group. Liraglutide vs glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 47381.